Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Delighted With Xiidra Deal Despite Eye-Watering Price

Executive Summary

Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.


Related Content

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration
Novartis CEO Issues Staunch Defense of Zolgensma As Sales Soar
Novartis Secures FDA Priority Review For Brolucizumab Thanks To PRV
Adios To Alcon In April As Novartis Confirms Spin-Off Date
Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Confirming Rumors, Novartis Buys AAA To Boost Oncology Business
The Eyes Have It For Shire With Lifitegrast Filing In Europe
Shire's Xiidra Gets Advantageous Label Covering Signs, Symptoms Of Dry Eye Disease


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts